Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This an open-label study designed to evaluate the anti-tumour activity and safety of Prolarix
in subjects with advanced hepatocellular carcinoma.
Prolarix is a chemotherapy comprised of tretazicar as prodrug and caricotamide as
co-substrate for the endogenous enzyme, NQO2.